Evidence map›Paper›PMID 34504133›Full record

ArticleScientific reports2021

Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells.

Rikke H Dahlrot, Julie A Bangsø, Jeanette K Petersen, Ann Mari Rosager, Mia D Sørensen, Guido Reifenberger, Steinbjørn Hansen, Bjarne W Kristensen

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Rikke H Dahlrot *Department of Pathology, Odense University Hospital, Odense, Denmark. rikke.dahlrot@rsyd.dk.ORCID 0000-0003-1538-4361
Julie A Bangsø *Department of Pathology, Odense University Hospital, Odense, Denmark.
Jeanette K PetersenDepartment of Pathology, Odense University Hospital, Odense, Denmark.ORCID 0000-0002-5093-5985
Ann Mari RosagerDepartment of Pathology, Odense University Hospital, Odense, Denmark.ORCID 0000-0003-2353-7612
Mia D SørensenDepartment of Pathology, Odense University Hospital, Odense, Denmark.ORCID 0000-0002-0105-2940
Guido ReifenbergerDepartment of Pathology, Odense University Hospital, Odense, Denmark.ORCID 0000-0002-1419-9837
Steinbjørn HansenDepartment of Oncology, Odense University Hospital, Odense, Denmark.ORCID 0000-0001-5651-6493
Bjarne W KristensenDepartment of Pathology, Odense University Hospital, Odense, Denmark.ORCID 0000-0002-6352-0826
University of Southern Denmark · DKOdense University Hospital · DKUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Survival of glioblastoma patients varies and prognostic markers are important in the clinical setting. With digital pathology and improved immunohistochemical multiplexing becoming a part of daily diagnostics, we investigated the prognostic value of the Ki-67 labelling index (LI) in glioblastomas more precisely than previously by excluding proliferation in non-tumor cells from the analysis. We investigated the Ki-67 LI in a well-annotated population-based glioblastoma patient cohort (178 IDH-wildtype, 3 IDH-mutated). Ki-67 was identified in full tumor sections with automated digital image analysis and the contribution from non-tumor cells was excluded using quantitative double-immunohistochemistry. For comparison of the Ki-67 LI between WHO grades (II-IV), 9 IDH-mutated diffuse astrocytomas and 9 IDH-mutated anaplastic astrocytomas were stained. Median Ki-67 LI increased with increasing WHO grade (median 2.7%, 6.4% and 27.5%). There was no difference in median Ki-67 LI between IDH-mutated and IDH-wildtype glioblastomas (p = 0.9) and Ki-67 LI was not associated with survival in glioblastomas in neither univariate (p = 0.9) nor multivariate analysis including MGMT promoter methylation status and excluding IDH-mutated glioblastomas (p = 0.2). Ki-67 may be of value in the differential diagnostic setting, but it must not be over-interpreted in the clinico-pathological context.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCohort StudiesFemaleGlioblastomaHumansKi-67 AntigenMaleMiddle AgedNeoplasm GradingPrognosisBiomarkers, TumorKi-67 Antigen

Identifiers

PMID34504133
PMCPMC8429554
OpenAlexW3198212650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.